Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo

Background: An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. Objectives: The purpose of this study was to clarify this unexpected finding in a larger sample size of patients stabilized after ac...

Full description

Bibliographic Details
Main Authors: Robert P. Giugliano, MD, SM, Baris Gencer, MD, Stephen D. Wiviott, MD, Jeong-Gun Park, PHD, Charles S. Fuchs, MD, MPH, Wolfram Goessling, MD, PHD, Thomas A. Musliner, MD, Andrew M. Tershakovec, MD, MPH, Michael A. Blazing, MD, Robert Califf, MD, Christopher P. Cannon, MD, Eugene Braunwald, MD
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:JACC. CardioOncology
Subjects:
acute coronary syndromes
cancer
ezetimibe
lipid-lowering therapy
lipids
malignancy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087320301708

Internet

http://www.sciencedirect.com/science/article/pii/S2666087320301708

Similar Items